SEARCH:   Advanced

Blood, 26 February 2009, Vol. 113, No. 9, pp. 1906-1908. Prepublished online as a Blood First Edition Paper on January 8, 2009; DOI 10.1182/blood-2008-10-182782. This Article Full Text (PDF) All Versions of this Article: blood-2008-10-182782v1 113/9/1906    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Weinberg, O. K. Articles by Arber, D. A. Search for Related Content PubMed PubMed Citation Articles by Weinberg, O. K. Articles by Arber, D. A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 6, 2008 Accepted December 18, 2008 Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system Olga K. Weinberg*, Mahesh Seetharam, Li Ren, Katie Seo, Lisa Ma, Jason D. Merker, Jason Gotlib, James L. Zehnder, and Daniel A. Arber Department of Pathology, Stanford University Medical Center, Stanford, CA, United States Department of Hematology, Stanford University Medical Center, Stanford, CA, United States Department of Medicine, Center for Clinical Investigation, Stanford University Medical Center, Stanford, CA, United States * Corresponding author; email: okw{at}stanford.edu. Although some studies have validated the 2001 WHO classification of acute myeloid leukemia (AML), including the importance of multilineage dysplasia, others have suggested that multilineage dysplasia correlates with unfavorable cytogenetics but has no independent impact on prognosis. In 2008, the revised WHO classification has expanded this category into "AML with myelodysplasia-related changes" (AML-MRC). We evaluated the clinical, pathologic, cytogenetic, and molecular features of one hundred AML patients using the 2008 WHO criteria. Patients underwent genetic screening for NPM1, FLT3-ITD, FLT3-D835 and CEBPA mutations. Compared to patients with AML, not otherwise specified (AML-NOS), patients with AML-MRC were significantly older (p=0.0141), presented with a lower hemoglobin (p=0.044), more frequently expressed CD14 (p=0.048), and exhibited a decreased frequency of CEBPA mutations (p=0.001). Multivariate analysis indicated that patients with AML-MRC had a significantly worse OS, PFS and CR compared to AML-NOS (all p<0.0001). These data support the clinical, morphologic and cytogenetic criteria for this 2008 WHO AML category. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood, July 30, 2009; 114(5): 937 - 951. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020